nuclear receptor subfamily 4 group A member 1Genealiases: GFRP1 · HMR · N10 · NAK-1 · NGFIB · NP10
Q-omics provides the consensus-scored NR4A1 profile across patient tissues and cancer cell-line models. NR4A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NR4A1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, NR4A1 RNA expression shows 16,984 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where NR4A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR4A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR4A1 survival associations across molecular data types. NR4A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR4A1 RNA expression–survival associations across cancer types. High NR4A1 expression shows unfavorable associations in UVM, THCA, ACC and ESCA, but favorable associations in KIRC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NR4A1 RNA expression.
This table summarizes NR4A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NR4A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR4A1 shows lower tumor expression in BLCA, KIRP, THCA, KICH, UCEC and KIRC. The BLCA box plot shows higher NR4A1 RNA expression in normal versus tumor tissue (log2 FC = −4.094, t-test p < 0.001).
This table shows molecular features associated with NR4A1 in patient tissues and cancer cell lines. In patient samples, NR4A1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NR4A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
